137052-08-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(Tetrahydro-2H-pyran-4-yl)ethanone is utilized as a key intermediate in the synthesis of various pharmaceuticals and organic compounds, leveraging its reactive properties to facilitate the creation of diverse medicinal agents.
Used in Flavoring and Fragrance Industry:
In the food and cosmetic industries, 1-(Tetrahydro-2H-pyran-4-yl)ethanone serves as a flavoring agent and fragrance, capitalizing on its agreeable scent to enhance the sensory experience of consumer products.
Used in Neurological Disorder Treatment:
1-(Tetrahydro-2H-pyran-4-yl)ethanone is explored for its potential pharmacological properties, particularly in the treatment of neurological disorders, where it may offer therapeutic benefits through its interaction with neurological pathways.
Used as an Analgesic Agent:
1-(Tetrahydro-2H-pyran-4-yl)ethanone is also considered for its analgesic properties, suggesting that it could be developed into a pain-relief medication, providing an alternative for managing various types of pain conditions.

InChI:InChI=1/C7H12O2/c1-6(8)7-2-4-9-5-3-7/h7H,2-5H2,1H3

Upstream product

• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 18815-73-1 methylzinc iodide 
• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 345216-96-8 methyl 4-acetyl-tetrahydro-2H-pyran-4-carboxylate 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 917-54-4 methyllithium 
• 156353-01-4 N-methoxy-N-methyltetrahydro-2H-pyran-4-carboxamide 
• 676-58-4 methylmagnesium chloride 
• 75-16-1 methylmagnesium bromide 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 141-97-9 ethyl acetoacetate 
• 111-44-4 3-oxa-1,5-dichloropentane 

Downstream Products

• 75338-17-9 3-oxo-3-(tetrahydropyran-4-yl)propionic acid methyl ester 
• 856414-68-1 3-oxo-3-(tetrahydropyran-4-yl)propionic acid ethyl ester 
• 1295521-50-4 4-(1-(2-pyrrolidin-1-yl-ethyl)-4-(tetrahydro-pyran-4-yl)-1H-imidazol-2-yl)-piperidine 
• 1604039-54-4 trimethyl((tetrahydro-2H-pyran-4-yl)ethynyl)silane 

Relevant academic research and scientific papers

Synthesis method for synthesizing 4-ethynyl-tetrahydropyran from 2, 2-dichloroethyl ether

The invention provides a synthetic method for synthesizing 4-ethynyl-tetrahydropyran from 2, 2 '-dichloroethyl ether, which comprises the following steps: (a) reacting a compound shown in a formula (I) with ethyl acetoacetate under the action of potassium carbonate and potassium iodide, carrying out aftertreatment, and carrying out sulfuric acid decarboxylation to obtain a compound shown in a formula (II); (b) removing hydrogen from the compound shown in the formula (II) by using an organic lithium reagent, and reacting with a diester chlorophosphate reagent to obtain a compound shown in a formula (III); and (c) removing the compound shown in the formula (III) by using an alkaline reagent, and reacting with alkyl chlorosilane to obtain a compound shown in a formula (IV). According to the preparation method, starting raw materials, process routes and post-treatment processes are different, the raw materials are simple and easy to obtain, the cost is low, and the preparation method is suitable for laboratory small-scale preparation and industrial production.

Copper(I)-Catalyzed Enantioselective Nucleophilic Borylation of Aliphatic Ketones: Synthesis of Enantioenriched Chiral Tertiary α-Hydroxyboronates

A new method was developed for the first catalytic enantioselective borylation of aliphatic ketones. A variety of substrates reacted efficiently with bis(pinacolato)diboron in the presence of a copper(I)/chiral N-heterocyclic carbene complex catalyst to furnish optically active tertiary α-hydroxyboronates with moderate to high enantioselectivities (up to 94 % ee). Notably, the product could be converted into the chiral tertiary alcohol derivative using a stereospecific boron functionalization process. The theoretical study of the mechanism for the enantioselectivity is also described.

PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (a) and pharmaceutically acceptable salts thereof. Compounds of Formula (a) have the general structure: (a) wherein each variable is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Abeta) protein, including Alzheimers Disease, are also disclosed.

PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE DERIVATIVES AS PDE9 INHIBITORS

Pyrazolo[4,3-d]pyrimidin-7(6H)-one derivatives represented by the general formula (I), wherein R1 represents hydrogen atom or methyl; when R1 represents hydrogen atom, then R2 represents cyclopentyl, tetrahydropyranyl, cyclohexyl, or cyclohexyl substituted with 1 or 2 halogen atoms; when R1 represents methyl, then R2 represents cyclopentyl; R3 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, and OCH3; and 6- to 10-membered heteroaryl with 1 to 3 heteroatoms selected independently form O, N and S; and Q represents C1-C3-alkylene group, which is unsubstituted or substituted with 1 to 3 C1-C3-alkyl groups; and their salts. The compounds are PDE9A inhibitors useful as m edicaments, in particular for treatment of cognitive function disorders and neurodegenerative diseases

PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (a) and pharmaceutically acceptable salts thereof. Compounds of Formula (a) have the general structure: (a) wherein each variable is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.

AKT INHIBITORS

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK2 receptor antagonists

Herein we describe the synthesis of a series of new potent tachykinin NK2 receptor antagonists by the modulation of the Cand N-terminal moieties of ibodutant (MEN 15596, 1). The Nterminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK2 receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK2 receptor. Selected compounds were tested in vivo confirming their activity as NK2 antagonists. In particular, after both iv and id administration to guinea pig, compound 61b was able to antagonize NK2-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).

PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN

The present invention is to provide a process for preparing an alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound represented by the formula (1): wherein R1 and R2 may be the same or different from each other, and represent a group which does not participate in the reaction, and R1 and R2 may be bonded to form a ring, and the ring may contain a hetero atom(s), and R3 represents a hydrocarbon group, which comprises reacting 4-acyltetrahydropyran represented by the formula (2): wherein R1 and R2 have the same meanings as defined above, and a carbonic acid diester represented by the formula (3): wherein R3 has the same meanings as defined above, and two R3s may be bonded to each other to form a ring, in the presence of a base, and a process for preparing 4-acyltetrahydropyran.